Business Overview: Milestone Pharmaceuticals Inc. (NASDAQ: MIST)

---

Executive Summary

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on cardiovascular medicines, built around its lead product, CARDAMYST (etripamil) nasal spray. CARDAMYST received FDA approval on December 12, 2025, as the first and only self-administered treatment for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to normal heart rhythm, and became available in U.S. retail pharmacies in the first quarter of 2026.

Milestone matters as a newly commercial-stage cardiovascular biotech: it has just crossed the critical threshold from clinical-stage to launched product, with a second, larger indication (atrial fibrillation with rapid ventricular rate) already showing positive Phase 2 data and headed toward Phase 3.

---

1. Core Business Model & How They Work

Milestone relies entirely on third-party contract manufacturers for its active pharmaceutical ingredient, nasal spray device, and finished product, focusing its own resources on clinical development, regulatory strategy, and commercial launch of CARDAMYST.

[ License/Develop Etripamil ] ➡️ [ Clinical Trials (PSVT, then AFib-RVR) ] ➡️ [ FDA Approval (Dec. 2025) ] ➡️ [ Third-Party Manufacturing ] ➡️ [ Specialized Sales Force & Pharmacy Distribution ]

Key Operational Drivers

1. Newly launched commercial product: CARDAMYST became available in U.S. retail pharmacies in Q1 2026, following FDA approval in December 2025 — Milestone is now executing its first real commercial launch rather than purely funding trials.
2. Targeted specialist sales force: approximately 60 sales representatives target cardiology and high-value primary care providers, reflecting a focused rather than broad commercial infrastructure appropriate to PSVT's roughly 40,000 treating physicians.
3. Self-administration as the core differentiator: etripamil's design — rapidly metabolized by blood esterases and absorbed nasally in under 10 minutes — enables patients to treat PSVT episodes themselves outside the emergency department, a meaningful departure from existing IV-based standard of care.
4. Pipeline expansion into AFib-RVR: a Phase 2 ReVeRA study showed statistically significant ventricular rate reduction versus placebo, and the company plans to pursue Phase 3 trials and a supplemental NDA pathway — a much larger addressable market than PSVT alone.
5. International expansion via partnerships: licensing partner Corxel (formerly JIXING) has an accepted NDA in China, and an EU Marketing Authorization Application under the trade name TACHYMIST was submitted to the EMA in November 2025.

---

2. Business Segments

Milestone operates as a single biopharmaceutical business without distinct reportable segments; this section is not applicable.

---

3. Product Portfolio

---

4. Competitive Landscape

• Current PSVT treatment: dominated by IV drugs (adenosine, verapamil, diltiazem) administered in an emergency department setting, plus catheter ablation for recurrent cases — CARDAMYST's self-administered, at-home design is a genuine departure from this paradigm, since no oral "pill in the pocket" option is currently approved.
• AFib competitors: generic antiarrhythmics and beta blockers dominate current treatment, with pipeline competitors including InCarda's InRhythm (flecainide) and Acesion's AAP30663 also targeting rapid, self- or point-of-care administration.
• Milestone explicitly notes that many competitors have substantially greater resources, reflecting its position as a newly commercial, single-product company facing both entrenched standards of care and well-funded pipeline rivals.

---

5. Strategic Strengths & Risks

Strengths (The Moat)

• First and only FDA-approved self-administered PSVT treatment, giving CARDAMYST a genuine first-mover advantage in a category with no oral or self-administered incumbent.
• Large pipeline optionality in AFib-RVR, a substantially bigger market than PSVT, already supported by positive Phase 2 data.
• International expansion already underway through the Corxel partnership (China) and EMA filing (EU), diversifying beyond U.S. commercial execution risk.
• Differentiated mechanism (rapid nasal absorption, esterase metabolism) that directly addresses the inconvenience and cost of emergency-department-based PSVT treatment.

Risks

• Extremely early commercial stage: CARDAMYST only became available in retail pharmacies in Q1 2026, so Milestone has essentially no track record of actual launch execution, physician adoption, or payer reimbursement dynamics yet.
• Reliance on third-party manufacturing for API, device, and finished product introduces supply-chain and quality risk outside Milestone's direct control.
• AFib-RVR remains pre-Phase 3, meaning the larger pipeline opportunity is still unproven in a pivotal trial and carries binary trial risk.
• Reimbursement and adoption uncertainty: a genuinely new category of self-administered cardiovascular treatment must overcome physician and payer inertia favoring established ED-based protocols.
• Small, focused sales force (60 reps) must build awareness among a specific, limited physician population before the product can achieve meaningful commercial scale.

---

6. Financial Overview

---

7. Summary Conclusion

Milestone Pharmaceuticals has reached the pivotal moment every clinical-stage biotech works toward: FDA approval and commercial launch of its first product, CARDAMYST, as the first self-administered treatment for PSVT. The differentiated, rapid-acting nasal spray design gives it a genuine first-mover position in a category previously limited to emergency-department IV treatment, and positive Phase 2 data in the much larger AFib-RVR indication gives the pipeline meaningful additional upside.

The company's biggest near-term risk is pure commercial execution: converting FDA approval and early retail pharmacy availability into real physician adoption, patient uptake, and payer reimbursement, all without an established sales track record, while simultaneously funding a Phase 3 program in AFib-RVR that will determine whether Milestone can become more than a single-indication company.